An Open-Label study to assess safety
An Open-Label study to assess the efficacy and potential for adrenal suppression following maximal use treatment with TA-102 topical formulations in subjects with Plaque Psoriasis.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
88
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Catawba Research, LLC
Charlotte, North Carolina, United States
number of participants with adrenal suppression
number of participants with adrenal suppression developed during the treatment with the study drug
Time frame: 84 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks